<sup>68</sup>Ga-Labeled Fibroblast Activation Protein Inhibitor (<sup>68</sup>Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the<sup>68</sup>Ga-FAPI PET Observational Trial
Lukas Kessler(German Cancer Research Center), Jens T. Siveke(German Cancer Research Center), Justin Ferdinandus(German Cancer Research Center), Anke Reinacher‐Schick(Ruhr University Bochum), Lale Umutlu(Essen University Hospital), Kim M. Pabst(West German Heart and Vascular Center Essen), Wolfgang P. Fendler(Essen University Hospital), Marco Niedergethmann(University Medical Centre Mannheim), Céline Lugnier(Ruhr University Bochum), Nader Hirmas(German Breast group), Rainer Hamacher(Essen University Hospital), Michael Nader(Klinik und Poliklinik für Nuklearmedizin), Waldemar Uhl(St. Josef-Hospital), Aleksandar Milošević(Essen University Hospital), Ken Herrmann(Essen University Hospital), David P. Witte(St. Josef-Hospital), Benedikt M. Schaarschmidt(Essen University Hospital)
Cited by 34
Related Papers
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial
|The Lancet Oncology|2007|808
IAP Guidelines for the Surgical Management of Acute Pancreatitis
|Pancreatology|2002|774
IAP Guidelines for the surgical management of acute pancreatitis
|Pancreatology|2002|531
Metabolic Imaging Predicts Response, Survival, and Recurrence in Adenocarcinomas of the Esophagogastric Junction
|Journal of Clinical Oncology|2006|464